000590 启迪药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-3.2863.5502.6275.3483.587
总资产报酬率 ROA (%)-2.0522.1781.6973.8112.613
投入资产回报率 ROIC (%)-2.4602.6442.0644.6423.289

边际利润分析
销售毛利率 (%)47.30952.42151.12355.27755.720
营业利润率 (%)-13.6484.9826.46814.08110.100
息税前利润/营业总收入 (%)-13.2727.8555.21311.8227.540
净利润/营业总收入 (%)-15.8726.1515.17411.7828.260

收益指标分析
经营活动净收益/利润总额(%)104.54739.88371.63275.46590.630
价值变动净收益/利润总额(%)0.1199.38712.6687.9541.375
营业外收支净额/利润总额(%)3.17132.075-3.643-1.237-0.517

偿债能力分析
流动比率 (X)2.0922.1691.9492.9623.159
速动比率 (X)1.4941.6461.5142.4992.843
资产负债率 (%)37.50636.74039.80429.5000.277
带息债务/全部投入资本 (%)16.00414.25816.1132.535-0.473
股东权益/带息债务 (%)461.535532.133453.6483,359.071-18,717.728
股东权益/负债合计 (%)165.452171.125150.362238.288260.797
利息保障倍数 (X)-16.13515.094-5.070-5.662-3.006

营运能力分析
应收账款周转天数 (天)21.84020.42612.6311.3015.168
存货周转天数 (天)323.459232.150215.184183.880150.289